Arbutus Biopharma Corp (ABUS) Stock AnalysisABUSStock AnalysisArbutus Biopharma Corp

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Arbutus Biopharma Corp is a good buy right now, primarily due to its recent announcement of a $230 million share buyback plan, which is expected to bolster market confidence and potentially drive the stock price higher. The current price of $5.07 is below the buyback range of $5.00 to $5.75, presenting a favorable entry point. Additionally, the stock has shown a 32.72% increase over the past year, indicating strong long-term growth potential. However, investors should be aware of the risk posed by the company's recent earnings report, which showed a loss of $0.03 per share in Q2 2026, reflecting ongoing volatility in profitability.

7 analysts cover ABUS: 6 rate it Buy, 1 Hold and 0 Sell. The average price target is 7.00.